Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06707532 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 27, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Trial Details
NCT Number NCT06707532
Lead Sponsor 4th Military Clinical Hospital with Polyclinic, Poland
Conditions
(from sponsor)		 Kidney Failure, Acute, Myopathy; Drugs, Heart Arrhythmia, Succinylcholine Sensitivity, Muscle Relaxation, General Anesthetic Drug Adverse Reaction, Projection
Related terms Acute Kidney Injury, Arrhythmias, Cardiac, Butyrylcholinesterase deficiency, Chronic Pain, Muscle Hypotonia, Myotoxicity
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov